Unilever To Exit OTC Diagnostics Business With Sale Of Unipath Subsidiary
This article was originally published in The Gray Sheet
Executive Summary
Unilever plans to divest its nearly $90 mil. Unipath women's health diagnostics business, including the Clearblue line of home pregnancy test kits, to focus on selected consumer brands, the firm said June 19 in announcing the intended sale